Gilteritinib improved survival for patients with acute myeloid leukaemia

Bookmark and Share
Published: 11 Apr 2019
Views: 448
Rating:
Save
Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA

Prof Alexander Perl gives a press conference at AACR 2019 on the findings of the ADMIRAL trial which showed that treatment with gilteritinib improved survival for patients with relapsed or refractory acute myeloid leukaemia (AML) in comparison with standard chemotherapy.